

EXHIBIT 1

AUSTRALIA

Patents Act 1990

IN THE MATTER OF
US Patent Application No. 09/446,109
by The University of Queensland

EXHIBIT SMT-1

This is Exhibit SMT-1 referred to in the Statutory Declaration by Stephen Maxwell Taylor

dated 12 MAY 2004

Before me:

Joni Luzzo



A person empowered to witness Statutory
Declarations under the laws of the Queensland,
Commonwealth of Australia

CURRICULUM VITAE

Steve M. Taylor

Personal:

Place of birth: England
Citizenship: British/Australian

Education:

B.Sc. (Hons.1), 1971 University of Sydney, Australia
Ph.D. (Pharmacology), 1978 University of Sydney, Australia

Post-Doctoral Experience:

1978-1982	Research Associate, Dept. of Pharmacology, School of Medicine, Oregon Health Sciences University, Portland, OR, U.S.A.
1982-1983	Research Fellow, Pulmonary Research Laboratory, Dept. of Medicine, St. Paul's Hospital, Vancouver, B.C., Canada
1983-1988	Research Assistant Professor, Dept. of Veterinary and Comparative Anatomy, Physiology and Pharmacology, & Dept. of Veterinary Microbiology & Pathology, Washington State University, Pullman, WA, U.S.A.
1988-1990	Senior Scientist, Immunetech Pharmaceuticals, San Diego, CA, U.S.A.
1990-1993	Lecturer in Pharmacology, University of Queensland Brisbane, Qld 4072, Australia
1994-1999	Senior Lecturer, University of Queensland Brisbane, Qld 4072, Australia
11/1999	Director of Pharmacology, Promics Pty Ltd
2000-	Reader in Pharmacology, Univ. Qld
2001-	Chief Scientist, Promics P/L

Membership in Professional Societies:

American Society for Pharmacology and Experimental Therapeutics
Leukocyte Society
Australian Society For Clinical and Experimental Pharmacology and
Toxicology
Australian Society for Cytokines, Inflammation and Leukocytes

Teaching:

1970-75 Demonstrator in Pharmacology, University of Sydney
1980-81 Visiting Lecturer in Pharmacology, Oregon Health
Sciences University, Portland, Oregon, USA
1983-84 Visiting Lecturer in Pharmacology, Department of
Pharmacology, College of Veterinary Medicine,
Washington State University, Pullman, WA, USA
1990- Lecturer/Senior Lecturer/Reader in Pharmacology,
University of Queensland

PUBLICATIONS

1. Malor, R., Griffin, C.J., and Taylor, S.M. Innervation of the blood vessels in the guinea pig atria. *Cardiovasc. Res.* 7: 95-104, 1973.
2. Malor, R., Taylor, S.M., Chesher, G.B. and Griffin, C.J. The intramural ganglia and chromaffin cells in quinea pig atria: an ultrastructural study. *Cardiovasc. Res.* 8: 731-744, 1974.
3. Taylor, S.M., Rodgers, R.M., Lynn, R.K., and Gerber, N. The seminal excretion, plasma half-life, tissue distribution and metabolism of naltrexone in the rabbit. *J. Pharmacol. Exp. Ther.* 213: 289-299, 1980.
4. Dickinson, R.G., Taylor, S.M., Kaufman, S.N., Rodgers, R.M., Gerber, N., and Baughman, W.J. Nonlinear elimination and choleretic effect of valproic acid in the monkey. *J. Pharmacol. Exp. Ther.* 213: 38-48, 1980.
5. Rogers, R.M., Taylor, S.M., Dickinson, R.G., Ilias, A.M., Lynn, R.K., and Gerber, N. Metabolism and choleretic effect of naltrexone in the isolated perfused rat liver. *Drug. Metab. Dispos.* 8: 390-396, 1980.
6. Koga, Y., Downes, H., and Taylor, S.M. Direct and indirect actions of dopamine on tracheal smooth muscle. *Naunyn Schmiedeberg's Arch. Pharmacol.* 315: 15-20, 1980.

7. Ilias, A.M., and Taylor, S.M. The seminal excretion, blood elimination, tissue distribution and metabolism of L-alpha-acetylmethadol in the rabbit. *Res. Commun. Subst. Abuse* 3: 443-452, 1982.
8. Downes, H., and Taylor, S.M. A potent, structurally specific stimulant action of procaine in bullfrog lung. *Comp. Biochem. Physiol.* 72(C): 39-43, 1982.
9. Taylor, S.M., and Downes, H. Bronchodilator mechanisms in bullfrog lung: differences in response to isoproterenol, theophylline and papaverine. *J. Pharmacol. Exp. Ther.* 223: 359-367, 1982.
10. Downes, H., and Taylor, S.M. Distinctive pharmacological profile of a nonadrenergic inhibitory system in bullfrog lung. *Br. J. Pharmacol.* 78: 339-351, 1983.
11. Taylor, S.M., Downes, H., Hirshman, C.A., Peters, J.E., and Leon, D. Pulmonary uptake of mannitol as an index of changes in lung epithelial permeability. *J. Appl. Physiol.* 55: 614-618, 1983.
12. Taylor, S.M., and Downes, H. Effect of stimulation of nonadrenergic inhibitory nerves on cyclic nucleotide levels in bullfrog lung. *Comp. Biochem. Physiol.* 77(C): 311-313, 1984.
13. Taylor, S.M., Pare, P.D., and Schellenberg, R.R. Cholinergic and nonadrenergic mechanisms in human and guinea pig airways. *J. Appl. Physiol.* 56: 958-965, 1984.
14. Armour, C.L., Lazar, N.M., Schellenberg, R.R., Taylor, S.M., Chan, N., Hogg, J.C., and Pare, P.D. A comparison of *in vivo* and *in vitro* human airway reactivity to histamine. *Am. Rev. Respir. Dis.* 129: 907-910, 1984.
15. Taylor, S.M., Bennett, G., Abbott, L.C., and Finnell, R.H. Anticonvulsant sensitivity in the mutant mouse, quaking. *European J. Pharmacol.* 118: 163-170, 1985.
16. Taylor, S.M., Pare, P.D., Armour, C.L., Hogg, J.C. and Schellenberg, R.R. Airway reactivity in Chronic Obstructive Pulmonary disease: Failure of *in vivo* methacholine responsiveness to correlate with cholinergic, adrenergic, or non-adrenergic responses *in vitro*. *Am. Rev. Resp. Dis.* 132: 30-35, 1985.
17. Taylor, S.M., Liggett, H.D., Laegreid, W.W., Silflow, R., and Leid, R.W. Arachidonic acid metabolism in bovine alveolar macrophages. Effect of calcium ionophore on lipoxygenase products. *Inflammation.* 10: 157-165, 1986.
18. Downes, H., Edelstein, R.A., and Taylor, S.M. Mechanisms of intrinsic tone in bullfrog lung; relaxant effects of indomethacin, ouabain, and potassium. *Brit. J. Pharmacol.* 87: 579-586, 1986.
19. Leid, R.W., Taylor, S.M., Heidel, J.R., Laegreid, W.W., Liggett, H.D., Potter, K.A., Silflow, R., and Breeze, R.G. Arachidonate metabolites from bovine alveolar and peripheral blood neutrophils. *Proceedings 14th World Congress of Diseases of Cattle.* 1: 549-554, 1986.
20. Husain, A., Pajka, S.F., Taylor, S.M., and Speth, R.C. Biological actions of monoiodo-angiotensin II. *J. Pharmacol. Exp. Ther.* 239: 71-77, 1986.

21. Finnell, R.H., Mohl, V.R., Bennett, G.B., and Taylor, S.M. The role of epoxidation in carbamazepine-induced teratogenesis. *Teratogenesis Mutagenesis and Carcinogenesis*. 6: 393-401, 1986.
22. Lyles, W.C., Taylor, S.M., Finnell, R.H., Lai, H., and Nathanson, N. Decreased muscarinic acetylcholine receptor number in the CNS of the tottering (tg/tg) mouse. *J. Neurochem.* 46: 977-982, 1986.
23. Willow, M., Taylor, S.M., Catterall, W.A., and Finnell, R.H. Down regulation of sodium channels in nerve terminals of spontaneously epileptic mice. *Cellular and Molecular Neurobiology*. 6: 213-220, 1986.
24. Taylor, S.M., and Finnell, R.H. Effect of quinidine and tetrodotoxin on non-adrenergic neurones in guinea-pig trachealis muscle. *Comp. Biochem. Physiol.* 86C: 11-15, 1987.
25. Pare, P.D., Armour, C.A., Taylor, S.M., Mullen, B., Moreno, R., Hogg, J.C. and Schellenberg, R.R. Airway hyperreactivity in COPD. Cause or effect, an *in vitro-in vivo* comparison. *Chest* 91: 41S-44S, 1987.
26. Taylor, S.M., Laegreid, W.W., Heidel, J., Straub, K., Liggitt, H.D., Silflow, R., Breeze, R.G., and Leid, R.W. Arachidonic and eicosapentaenoic acid metabolism in bovine peripheral blood neutrophils and platelets: effect of calcium ionophore. *J. Leukocyte Biol.* 42: 253-262, 1987.
27. Finnell, R.H., Shields, H., Taylor, S.M., and Chernoff, G.F.. Strain differences in phenobarbital-induced teratogenesis in mice. *Teratology*. 35: 177-185, 1987.
28. Laegreid, W.W., Taylor, S.M., Liggitt, H.D., Straub, K., Silflow, R., Breeze, R.G., and Leid, R.W. Production of lipoxygenase metabolites of eicosapentaenoic acid by bovine alveolar macrophages *in vitro*. *Inflammation* 12: 503-514, 1988.
29. Finnell, R.H., Abbott, L.C., and Taylor, S.M. The fetal hydantoin syndrome: answers from a mouse model. *Reproductive Toxicology*. 3:127-133, 1989.
30. Laegreid, W.W., Taylor, S.M., Englen, M.D., Silflow, R.M., Liggitt, H.D., and Leid, R.W. Stimulus-selective production of cyclo-oxygenase and lipoxygenase metabolites of arachidonic acid by bovine alveolar macrophages. *Inflammation* 13: 233-244, 1989.
31. Laegreid, W.W., Liggitt, H.D., Silflow, R.M., Evermann, J.R., Taylor, S.M., and Leid, R.W. Reversal of virus-induced alveolar macrophage bactericidal dysfunction by cyclo-oxygenase inhibition *in vitro*. *J. Leukocyte Biol.* 45: 283-292, 1989
32. Laegreid, W.W., Taylor, S.M., Liggitt, H.D., Evermann, J., Silflow, R and R.W. Leid. Virus-induced enhancement of arachidonate metabolism by bovine alveolar macrophages *in vitro*. *J. Leukocyte Biol.* 45: 293-300, 1989.
33. Englen, M.D., Taylor, S.M., Laegreid, W.W., Liggitt, H.D., Silflow, R.M. and Leid, R.W. Stimulation of arachidonic acid metabolism in silica-exposed alveolar macrophages. *Exp. Lung Research.* 15: 511-526, 1989.
34. Heidel, J.R., Taylor, S.M., Laegreid, W.W., Silflow, R.M., Liggitt, H.D., and Leid, R.W. Characterisation of arachidonic acid metabolism, superoxide production, and

bacterial killing in bovine circulating neutrophils and elicited alveolar neutrophils. *J. Leukocyte Biol.* 46: 41-50, 1989

35. Heidel, J.R., Taylor, S.M., Laegreid, W.W., Silflow, R.M., Liggitt, H.D. and Leid, R.W. *In vivo* chemotaxis of bovine neutrophils by 5-lipoxygenase metabolites of arachidonic and eicosapentaenoic acid. *Am. J. Pathology*. 134: 671-676, 1989.
36. Silflow, R.M., Foreyt, W.J., Taylor, S.M., Laegreid, W.W., Liggitt, H.D. and R.W. Leid. Comparison of pulmonary defense mechanisms in bighorn and domestic sheep. *J. Wildlife Diseases* 25: 514-520, 1989
37. Heidel, J.R., Sassenfeld, C.R., Maliszewski, R.M. Silflow, Baker, P.E, Taylor, S.M. and R.W. Leid. Functional studies of bovine alveolar neutrophils elicited with recombinant bovine IL-1 β . *J. Immunol.* 144: 1037-1041, 1990
38. Taylor, S.M., Laegreid, W.W., Englen, M.D., Dani, G., Silflow, R., Liggitt, H.D. and R.W. Leid. Influence of extracellular calcium on arachidonic acid metabolism in alveolar macrophages. *J. Leukocyte Biol.* 48: 502-511, 1990
39. Englen, M.D., Taylor, S.M., Laegreid, W.W., Silflow, R., Banks, K. and R.W. Leid. Arachidonic acid metabolism in caprine alveolar macrophages. *Inflammation* 14: 239-245, 1990
40. Englen, M.D., Taylor, S.M., Laegreid, W.W., Silflow, R.M. and R.W. Leid. Effects of different silicas on arachidonate metabolism in alveolar macrophages. *Exp. Lung Res.* 16: 691-709, 1990
41. Heidel, J.R., Taylor, S.M., Silflow, R.M. and R.W. Leid. Characterisation of arachidonic acid metabolism, superoxide production and bacterial killing by bovine alveolar neutrophils elicited with LTB4 and zymosan activated plasma. *Inflammation* 1991, 15: 31-42
42. Silflow, R.M., Taylor, S.M., Laegreid, W.W., Liggitt, H.D. and R.W. Leid. Comparison of arachidonic acid metabolism by alveolar macrophages in bighorn and domestic sheep. *Inflammation* 14: 43-54, 1991
43. Englen, M.D., Taylor, S.M., Laegreid, W.W., Silflow, R. M. and R.W. Leid. Diminished arachidonic acid release by bovine alveolar macrophages exposed to surface-modified silica. *Am. J. Respir. Cell Mol. Biol.* 6: 527-534, 1992
44. Ember, J.A., Sanderson, S. D., Taylor, S.M., Kawahara, M., and T.E.Hugli. Biologic activity of synthetic analogs of C5a anaphylatoxin. *J. Immunol.* 148: 3165-3173, 1992
45. Taylor, S.M., Heron, A.E., Cannell, G.R. and T.H. Florin. Pressor effect of ethanol in the isolated, perfused human placental lobule. *Eur. J. Pharmacol.* 270: 371-374, 1994
46. Taylor, S.M., Finch, A.M., Heron, A.E., Brown, L.C. and T.H. Florin. Reversibility of tachyphylaxis to C5a in guinea-pig tissues, the perfused human placental lobule and the umbilical artery. *Inflammation* 18: 645-657, 1994
47. Sanderson, S.D., Ember, J.A., Kirmarsky, L., Sherman, S.A., Finch, A. M and S.M. Taylor. Decapeptide agonists of human C5a: The relationship between

conformation and spasmogenic and platelet aggregatory activities. *J. Med. Chem.* 37: 3171-3180, 1994

48. Shiels, I.A., Bowler, S.D. and S.M. Taylor. Airway smooth muscle proliferation in asthma: the potential of vascular leakage to contribute to pathogenesis. *Med. Hypotheses.* 45: 37-40, 1995

49. Finch, AM, Heron AE, Tolhurst SL, Florin, TH, Sanderson SD & SM Taylor. The effect of C5a and U46619 on the isolated, perfused human placental lobule: development of a method for the on-line estimation of tissue fluid accumulation *J. Pharmacol. Toxicol Methods.* 34: 133-141, 1995

50. Sanderson SD, Kirnarsky L, Sherman S, Ember JA, Finch AM & S M Taylor. Decapeptide agonists of human C5a: the relationship between conformation and neutrophil response, *J. Med. Chem.* 38: 3669-3675, 1995

51. Shiels IA, Bowler, SD and SM Taylor. Homologous serum increases fibronectin expression and cell adhesion in airway smooth muscle cells. *Inflammation* 20: 373-388, 1996 7

52. Kawatsu, R, Sanderson, SD, Blance, I, Kendall, N, Finch, AM, Taylor, SM and D. Colcher. Conformationally biased analogues of human C5a mediate changes in vascular permeability. *J. Pharmacol. Exp. Therap.* 278: 432-440, 1996 11

53. Finch, AM, Vogen, SM, Sherman, SA, Kirnarsky, L, Taylor, SM and SD Sanderson. A biologically active conformer of the effector region of human C5a and the modulatory effects of N-terminal receptor binding determinants on activity. *J. Med. Chem.* 40: 877-884, 1997 22

54. Temporo, RM, Hollingsworth, MA, Burdick, MD, Finch, AM, Taylor SM, Vogen SM, Morgan EL and Sanderson, SD Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin *J. Immunol.* 158: 1377-1382, 1997 15

55. Shiels, IA, Zhang, S, Ambler, J and SM Taylor. Homologous serum induces phenotypic change and fibronectin expression in cultured retinal epithelial cells *Med. Hypotheses.* 50: 113-117, 1998. 6

56. Wong, AK, Finch, AM, Pierons, G, Taylor, SM and Fairlie, DP. Molecular probes for G-protein coupled receptors. Conformationally constrained antagonists derived from the C-terminus of human plasma protein C5a. *J. Med. Chem.* 41: 3417-3425, 1998 20

57. Zhang, S., I. A. Shiels, J. Ambler and S. M. Taylor. Pirfenidone reduces fibronectin synthesis by cultured human RPE cells. *Aust. N. Z. J. Ophthalmol.* 26, 574-576, 1998. 5

58. Vogen,SM, Finch, AM, Wadi, K, Thatcher, J, Monk, PN, SM Taylor & Sanderson, SD. The role of the amino terminal end of decapeptide agonists of C5a in receptor binding and activation: Nature of the interaction of position 68 of C5a and Glu199 of the C5a receptor. *Peptide Res.* 53: 8-17, 1999

59. Shiels, IA, SD Sanderson &SM Taylor. A multi-species, arterially-perfused eye model of uveitis to test a novel anti-inflammatory agent, pirfenidone. *Aust. Vet. J.* 77: 100-104, 1999.

60 Short, A, Wong, AK, Finch, AM, Haaima, G, Shiels, IA, Fairlie, DP & SM Taylor. Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat. *Br. J. Pharmacol.* 126: 551-554, 1999 25

61 Paczkowski NJ, Finch, AM, Whitmore, J, Short, AJ, Wong, AK, Monk, PN, Cain SA, Fairlie, DP and SM Taylor Pharmacological characterisation of antagonists of the C5a receptor *Br J Pharmacol* 128: 1461-1466, 1999. 30

62 Finch, AM, Wong, AK, Paczkowski, NJ, Wadi, SK, Craik, D, Fairlie, DP and S. M. Taylor. Low molecular weight peptidic and cyclic antagonists of the C5a receptor *J. Med Chem.* 42: 1965-1974, 1999 34

63 Wong, A.K.; Taylor, S. M.; Fairlie, D. P. Development of C5a receptor antagonists *Investigational Drugs* 2: 686-693, 1999

64 Shiels, IA, Bowler SD and SM Taylor The effects of salbutamol, beclomethasone and dexamethasone on growth and fibronectin expression by cultured airway smooth muscle cells. *Inflammation* 23: 321-331, 1999 8

65 Short, AJ, Paczkowski, NJ, Vogen, SM, Sanderson SD and S M Taylor. Response-selective C5a agonists: differential effects on neutropenia and hypotension in the rat. *Br. J. Pharmacol.* 128: 511-514, 1999. 10

66 Zhang, S, Shiels IA & SM Taylor. Homologous serum stimulated fibronectin synthesis in human retinal pigmented epithelial cells. *Aust. N. Z. J. Ophthalmol* 27: 247-249, 1999

67 Vogen SM, Finch AM, Wadi SK, Thatcher J, Monk PN, Taylor SM, Sanderson SD The influence of Lys68 in decapeptide agonists of C5a on C5a receptor binding, activation and selectivity *J Peptide Res.* 53: 8-17 1999 9

68 Shiels, IA, Taylor, SM and DP Fairlie. Targeting vascular leakage and structural change in chronic inflammatory diseases. *Med Hypotheses* 54: 193-197, 2000 3

69 Ulrich, JT, Cieplak, W, Paczkowski NJ, Taylor SM and SD Sanderson. Induction of an antigen-specific CTL immune response by a conformationally biased agonist of human C5a anaphylatoxin as a molecular adjuvant *J. Immunol.* 164: 5492-5498, 2000 5

70 Haynes DR, Harkin, DJ, Bignold, LP, Hutchens, M, Taylor, SM. & DP Fairlie. Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production *in vitro* by a new C5a receptor antagonist. *Biochem. Pharmacol.* 60: 729-733, 2000 17

71 Strachan, AJ, Woodruff, TM Haaima, G, Fairlie, DP and SM Taylor The role of the complement system in ischemia-reperfusion injury. Inhibition of the reverse passive Arthus reaction and endotoxic shock in rats by a small molecule C5a receptor antagonist. *J. Immunol.* 164: 6560-6565, 2000 34

72 Taylor, SM & DP Fairlie. Regulators of the anaphylatoxin C5a. *Expert Opinion in Therapeutic Patents.* 10: 449-458, 2000 3

73 Shiels IA, Taylor SM, Fairlie DP Cell phenotype as a target of drug therapy in chronic inflammatory diseases *Med Hypotheses* 54 : 193-197, 2000 3

74 Woodruff TM, AJ Strachan, SD Sanderson, P N Monk, AK Wong,[†] DP Fairlie and S M Taylor. Species variance in the binding affinity of new low molecular weight antagonists and agonists of the C5a receptor *Inflammation*, 25 :171-177, 2001 9

75 Cain S. A.; Woodruff, T. M.; Taylor, S. M.; Fairlie, D. P.; Monk, P. N. Mutations in the first extracellular loop of the human C5a receptor differentially affect responses to agonists and antagonists *Biochem. Pharmacol.* 61:1571-9, 2001 6

76 Stocks, SZ, Taylor, SM and I.A. Shiels. TGF- β induced α -smooth muscle actin expression and fibronectin synthesis in cultured human retinal pigment epithelial cells *Clin Experiment Ophthalmol.* 29:33-7, 2001 3

77 Taylor SM, Sherman SA, Kirnarsky L and SD Sanderson Development of response-selective agonists of human C5a anaphylatoxin: conformational, biological, and therapeutic considerations. *Curr Med Chem* 8:675-84, 2001 3

78 Miric G, Dallemande C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. *Br J Pharmacol.* ;133:687-94, 2001. 18

79 Strachan, AJ, IA Shiels, RC Reid, DP Fairlie, SM Taylor Inhibition of immune-complex mediated dermal inflammation following either oral or topical administration of a small molecule C5a receptor antagonist. *Br J Pharmacol* 134: 1778-1786, 2001 14

80 Vogen SM, Paczkowski NJ, Kirnarsky L, Short A, Whitmore JB, Sherman SA, Taylor SM, Sanderson SD. Differential activities of decapeptide agonists of human C5a: the conformational effects of backbone N-methylation. *Int Immunopharmacol.* 1:2151-62, 2001.

81 Mirkovic S, AL Seymour, A Fenning, A Strachan, S B Margolin, S M Taylor and L Brown Selective reversal of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats *Br J Pharmacol* 135; 961-968, 2002 7

82 Arumugam TV, IA Shiels, S B Margolin, SM Taylor and L Brown Pirfenidone attenuates ischaemia-reperfusion injury in the rat small intestine *Clin. Exp. Physiol. Pharmacol.* 29, 996-1000, 2002 1

83 Arumugam, TV, IA. Shiels, TM. Woodruff, RC Reid, DP. Fairlie and SM. Taylor. A small molecule C5a receptor antagonist protects the rat small intestine against ischemia-reperfusion injury. *J. Surg. Res.* 103: 260-267, 2002 16

84 Woodruff TM, Strachan AJ, Dryburgh, N, Shiels IA, Reid RC, DP. Fairlie, and SM Taylor Anti-arthritic activity of an orally active C5a receptor antagonist against antigen-induced monoarticular arthritis in the rat. *Arthritis and Rheumatism* 46: 2476-2485, 2002 6

85 ArumugamTV, Shiels IA, Strachan AJ, Abbenanate G, Fairlie DP and SM. Taylor A small molecule C5a receptor antagonist protects kidneys against ischemia-reperfusion injury in rats. *Kidney International* 63:134-42, 2003 13

86 Harkin, DW, BB Rubin, SM Taylor, AD Romaschin, TF Lindsay Complement C5a Receptor Antagonist Attenuates Multiple Organ Injury in a Model of Ruptured Abdominal Aortic Aneurysm *J. Vasc. Surg.* 39: 196-206, 2004

87 Arumugam, T, Arnold,N , Newman,M Reid, RC, Hansford, K, Fairlie, DP Shiels, IA and SM Taylor. Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA₂, COX-1 and COX-2 selective inhibitors, and an LTC₄ receptor antagonist. *Br J Pharmacol.* 140:71-80, 2003

88 Woodruff TM, Arumugam, T, Shiels IA, Reid RC, DP. Fairlie, and SM Taylor A potent C5a receptor antagonist inhibits markers of local and remote organ injury following tourniquet-induced limb ischemia-reperfusion in rats. *J. Surg. Res.* 116: 81-90, 2004

89 Woodruff, T. M.; Arumugam, T. V.; Shiels, I. A.; Reid, R. C.; Fairlie, D. P.; Taylor, S. M. A Potent C5a Receptor Antagonist Inhibits and Reverses Disease Pathology in a Rat Model of Inflammatory Bowel Disease, *J. Immunol.* 171: 5514-5520, 2003.

90 Reid, RC, Abbenante, G, Taylor, SM and DP Fairlie A Convergent Solution Phase Synthesis of the Macrocycle, Ac-Phe-[Orn-Pro-D-Cha-Trp-Arg], a Potent New Anti-Inflammatory Drug *J. Org. Chem.* 68: 4464-71, 2003

91 Proctor, LM Arumugam, TV, Shiels, IA, Woodruff,TM, Reid, RC Fairlie, DP and SM Taylor Comparative Anti-inflammatory Activities of Antagonists to C3a and C5a Receptors in a Rat Model of Intestinal Ischaemia/Reperfusion Injury *Br J Pharmacol* Accepted for Publication 2004

92 Arumugam, TV IA Shiels, TM Woodruff, DN Granger and SM Taylor The role of the complement system in ischemia-reperfusion injury: a review *Shock* 21:401-409, 2004

93 Arumugam, TV , TM Woodruff, LM Proctor, S Pollitt, SZ Stocks, IA Shiels, RC Reid, DP Fairlie and SM Taylor. Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats *J. Hepatol.* In Press 2004

94 Arumugam TV, TM Woodruff, LM Proctor, KA Hansford, C Reid, IA Shiels, DP Fairlie and SM Taylor Beneficial effects of a new sPLA₂ inhibitor and C5a receptor antagonist against cold storage-induced ischaemic liver and renal injury in UW solution Submitted

95 March, DR LM Proctor, MJ Stoermer, R Sbaglia, G Abbenante, RC Reid, K Wadi, JD Tyndall, SM Taylor, and DP Fairlie. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Structure-activity relationships *Mol. Pharmacol.* 65:868-79, 2004

96 Woodruff, TM, N Dryburgh, RC. Reid, KA. Hansford, DP. Fairlie, SM. Taylor and IA. Shiels Anti-Inflammatory Properties of an Orally Active Secretory Phospholipase A₂ Inhibitor in Antigen-Induced Monoarticular Arthritis in the Rat. Submitted

97 Cain, SA, Taylor, SM, Proctor LM, Fairlie, DP and PN Monk The effects of mutating putative activation switch residues on the activity of a cyclic peptide C5a receptor antagonist Submitted

98 Shiels, IA, M Pappas, R Reid, DP Fairlie, SM Taylor. An inhibitor of the secretory phospholipase A₂ enzyme reduces contractions in rat uterus. Submitted

99 Proctor, LM, Woodruff, TM, Packowski, NJ, Strachan, AJ, Monk, PM, Reid, RC, Ross, PA, Fairlie, DP and SM Taylor. Peptide Analogues of the C-terminus of C3a and C5a have Differential Hemodynamic Effects in the Rat. Submitted.

100 Woodruff, TM, TV Arumugam, IA. Shiels, M L Newman, RC Reid, DP Fairlie, and SM Taylor. A Potent and Selective Inhibitor of Group IIa Secretory Phospholipase A₂ Protects Rats From TNBS-Induced Colitis submitted

Book Chapters

Taylor SM & DP Fairlie Discovery of Potent Cyclic Antagonists of Human C5a Receptors. In: Structural Biology of the Complement System. 2004 Eds. J Lambris and D Morikis Marcel Dekker NY USA.

Patents

- 1 Sanderson SD, Kirnarsky L, Sherman S, & SM Taylor. High affinity response-selective C-terminal analogs of C5a. *U.S. Patent 5,942,599* Issued 24/8/1999
- 2 Taylor, S. M.; Fairlie, D. P. "Cyclic Agonists and Antagonists of C5a Receptors and G Protein-Coupled Receptors" Aust. Patent 744991, 25 June 1997. International Patent PCT/AU98/00490, Filed 25 June 1998.
- 3) Shiels, I.; Taylor, S.M.; Fairlie, D. P. "A new method for the treatment of dysmenorrhoea and menstrual side effects : the use of inhibitors of human secretory phospholipases A2" filed as "Compositions and methods of using them" Aust. Provisional Patent, filed 14 July, 2000, PQ8764/00. *International Patent Application* 2004, PCT/AU01/00858
- 4) Taylor SM, Shiels IA and Brown LC. Use of C5a Receptor Antagonist in the Treatment of Fibrosis. *International Patent PCT/AU03/00415, Filed 8 April 2004.*

- 5) Taylor SM, Shiels IA, Fairlie DP. G Protein-Coupled Receptor Antagonists. *International Patent PCT/AU02/01427, Filed 17 October 2002*
- 6) Woodruff TM and Taylor SM. Treatment of Inflammatory Bowel Disease. *International Patent PCT/AU2003/001365, Filed 17 October 2002.*
- 7) *Taylor, S. M., Shiels, I.A* Treatment of osteoarthritis by C5a antagonists. International Patent PCT/AU2003/001373, Filed 17 October 2002.
- 8) Shiels IA, Taylor SM and Fairlie D. Treatment of Hypersensitivity Conditions. *International Patent PCT/AU2003/001374, Filed 17 October 2002.*
- 9) Lindsay T, Harkin D and Taylor SM. Treatment of Haemorrhagic Shock. *Australian Patent Application No 2003902354, Filed 15 May 2003.*
- 10) Taylor SM and Shiels IA. Treatment of Burns. *Australian Patent Application No 2003902586, Filed 26 May 2003.*
- 11) *Woodruff TM, Shiels IA and Taylor SM Treatment of neurological conditions.* Australian Provisional Patent Application , Filed April 2004.